{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:18:22Z","timestamp":1792448302173,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T00:00:00Z","timestamp":1574812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011074","name":"Universit\u00e9 de Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004100","name":"Labex","doi-asserted-by":"publisher","award":["ANR-11-LABX-0042"],"award-info":[{"award-number":["ANR-11-LABX-0042"]}],"id":[{"id":"10.13039\/501100004100","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","award":["00060911"],"award-info":[{"award-number":["00060911"]}],"id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.nbd.2019.104643","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T23:31:34Z","timestamp":1572737494000},"page":"104643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Prior MDMA administration aggravates MPTP-induced Parkinsonism in macaque monkeys"],"prefix":"10.1016","volume":"134","author":[{"given":"Mathilde","family":"Millot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Saga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Duperrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"M\u00e9t\u00e9reau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maude","family":"Beaudoin-Gobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Sgambato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.nbd.2019.104643_bb0005","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S1474-4422(05)70119-8","article-title":"Striatal deformities of the hand and foot in Parkinson's disease","volume":"4","author":"Ashour","year":"2005","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.nbd.2019.104643_bb0010","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/brain\/awv183","article-title":"Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate","volume":"138","author":"Beaudoin-Gobert","year":"2015","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.nbd.2019.104643_bb0015","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2019.104643_bb0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuropharm.2017.06.008","article-title":"Widespread reduction of dopamine cell bodies and terminals in adult rats exposed to a low dose regimen of MDMA during adolescence","volume":"123","author":"Cadoni","year":"2017","journal-title":"Neuropharmacology."},{"issue":"2","key":"10.1016\/j.nbd.2019.104643_bb0025","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/sj.npp.1300033","article-title":"Inhibition of 5-HT neurotransmission increases clonidine protective effects on naloxone-induced conditioned place aversion in morphine-dependent rats","volume":"28","author":"Caill\u00e9","year":"2003","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.nbd.2019.104643_bb0030","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fmed.2019.00090","article-title":"The story of the dopamine transporter PET tracer LBT-999: from conception to clinical use","volume":"6","author":"Chalon","year":"2019","journal-title":"Front. Med. (Lausanne)."},{"issue":"14","key":"10.1016\/j.nbd.2019.104643_bb0035","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/mds.25646","article-title":"MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice","volume":"28","author":"Costa","year":"2013","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.nbd.2019.104643_bb0040","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1523\/JNEUROSCI.19-12-05096.1999","article-title":"Altered serotonin innervation patterns in the forebrain of monkeys treated with (+\/\u2212)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery","volume":"19","author":"Hatzidimitriou","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2019.104643_bb0045","first-page":"29","article-title":"Nondopaminergic neurons in Parkinson's disease","volume":"91","author":"Hirsch","year":"2003","journal-title":"Adv. Neurol."},{"issue":"3","key":"10.1016\/j.nbd.2019.104643_bb0050","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/brain\/awx361","article-title":"Parkinson's disease tremors and serotonin","volume":"141","author":"Jankovic","year":"2018","journal-title":"Brain."},{"key":"10.1016\/j.nbd.2019.104643_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-7091-6360-3_1","article-title":"Post mortem studies in Parkinson's disease- is it possible to detect brain areas for specific symptoms?","volume":"56","author":"Jellinger","year":"1999","journal-title":"J. Neural Transm. Suppl."},{"issue":"11","key":"10.1016\/j.nbd.2019.104643_bb0060","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/mds.20223","article-title":"Ecstasy use-Parkinson's disease link tenuous","volume":"19","author":"Jerome","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2019.104643_bb0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.parkreldis.2018.02.047","article-title":"Presynaptic striatal dopaminergic depletion predicts the later development of freezing of gait in de novo Parkinson's disease: an analysis of the PPMI cohort","volume":"51","author":"Kim","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"issue":"11","key":"10.1016\/j.nbd.2019.104643_bb0070","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/mds.10643","article-title":"What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?","volume":"18","author":"Kish","year":"2003","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2019.104643_bb0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.brainres.2012.08.015","article-title":"6-OHDA injections into A8-A9 dopaminergic neurons modelling early stages of Parkinson's disease increase the harmaline-induced tremor in rats","volume":"1477","author":"Kolasiewicz","year":"2012","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.nbd.2019.104643_bb0080","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1056\/NEJMc030208","article-title":"MDMA and Parkinsonism","volume":"349","author":"Kuniyoshi","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"Pt 9","key":"10.1016\/j.nbd.2019.104643_bb0085","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/brain\/aww162","article-title":"The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease","volume":"139","author":"Maillet","year":"2016","journal-title":"Brain J. Neurol."},{"issue":"7","key":"10.1016\/j.nbd.2019.104643_bb0090","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/cercor\/bhp236","article-title":"Opposing effects of 5,7-DHT infusions into the orbitofrontal cortex and amygdala on flexible responding","volume":"20","author":"Man","year":"2010","journal-title":"Cereb. Cortex"},{"issue":"2","key":"10.1016\/j.nbd.2019.104643_bb0095","first-page":"283","article-title":"Changes in 5-HT2A receptor expression in untreated, de novo patients with Parkinson's disease","volume":"4","author":"Melse","year":"2014","journal-title":"J. Park. Dis."},{"issue":"18","key":"10.1016\/j.nbd.2019.104643_bb0100","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJM199905063401817","article-title":"Parkinsonism after taking ecstasy","volume":"340","author":"Mintzer","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nbd.2019.104643_bb0105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.pneurobio.2015.09.011","article-title":"Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms","volume":"155","author":"Moratalla","year":"2017","journal-title":"Prog. Neurobiol."},{"issue":"3","key":"10.1016\/j.nbd.2019.104643_bb0110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00702-017-1722-y","article-title":"Non-human primate models of PD to test novel therapies","volume":"125","author":"Morissette","year":"2018","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"Pt 11","key":"10.1016\/j.nbd.2019.104643_bb0115","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1093\/brain\/awm208","article-title":"A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery","volume":"130","author":"Mounayar","year":"2007","journal-title":"Brain."},{"issue":"2","key":"10.1016\/j.nbd.2019.104643_bb0120","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/0271678X18770107","article-title":"Cerebral serotonin transporter measurements with [11C]DASB: a review on acquisition and preprocessing across 21 PET centres","volume":"39","author":"N\u00f8rgaard","year":"2019","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"11","key":"10.1016\/j.nbd.2019.104643_bb0125","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/mds.10623","article-title":"Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs","volume":"18","author":"O'Suilleabhain","year":"2003","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/j.nbd.2019.104643_bb0130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ana.24859","article-title":"Serotonin transporter in Parkinson's disease: a meta-analysis of positron emission tomography studies","volume":"81","author":"Pagano","year":"2017","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.nbd.2019.104643_bb0135","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00702-017-1823-7","article-title":"The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies","volume":"125","author":"Pagano","year":"2018","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"3","key":"10.1016\/j.nbd.2019.104643_bb0140","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/brain\/awx376","article-title":"Progression of tremor in early stages of Parkinson's disease: a clinical and neuroimaging study","volume":"141","author":"Pasquini","year":"2018","journal-title":"Brain."},{"issue":"10","key":"10.1016\/j.nbd.2019.104643_bb0145","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1093\/brain\/awv215","article-title":"Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease","volume":"138","author":"Qamhawi","year":"2015","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.nbd.2019.104643_bb0150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000026664","article-title":"(+\/\u2212)3,4-Methylenedioxymethamphetamine ('Ecstasy\u2019)-induced serotonin neurotoxicity: studies in animals","volume":"42","author":"Ricaurte","year":"2000","journal-title":"Neuropsychobiology"},{"issue":"12","key":"10.1016\/j.nbd.2019.104643_bb0155","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S1474-4422(09)70293-5","article-title":"Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms","volume":"8","author":"Rodriguez-Oroz","year":"2009","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.nbd.2019.104643_bb0160","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1002\/mds.27205","article-title":"Structural abnormality of substantia nigra induced by methamphetamine abuse","volume":"32","author":"Rumpf","year":"2017","journal-title":"Mov. Disord."},{"issue":"1\u20132","key":"10.1016\/j.nbd.2019.104643_bb0165","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0006-8993(90)90069-N","article-title":"Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys","volume":"519","author":"Schneider","year":"1990","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/j.nbd.2019.104643_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056438","article-title":"Illicit stimulant use is associated with abnormal substantia nigra morphology in humans","volume":"8","author":"Todd","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2019.104643_bb0175","series-title":"Molecular Imaging. Radiopharmaceuticals for PET and SPECT","author":"Vallabhajosula","year":"2009"},{"issue":"4","key":"10.1016\/j.nbd.2019.104643_bb0180","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.pbb.2008.04.010","article-title":"A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model","volume":"90","author":"Vanover","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"19\u201320","key":"10.1016\/j.nbd.2019.104643_bb0185","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1007\/s00213-016-4396-5","article-title":"The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies","volume":"233","author":"Vegting","year":"2016","journal-title":"Psychopharmacology"}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996119303183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996119303183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:18:20Z","timestamp":1760851100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996119303183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":37,"alternative-id":["S0969996119303183"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2019.104643","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prior MDMA administration aggravates MPTP-induced Parkinsonism in macaque monkeys","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2019.104643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104643"}}